<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02176928</url>
  </required_header>
  <id_info>
    <org_study_id>20130161</org_study_id>
    <secondary_id># W81XWH-13-1-0479</secondary_id>
    <nct_id>NCT02176928</nct_id>
  </id_info>
  <brief_title>Sleep-Disordered Breathing in Chronic SCI</brief_title>
  <official_title>Sleep-Disordered Breathing in Chronic SCI: A Randomized Controlled Trial of Treatment Impact on Cognition, Quality of Life, and Cardiovascular Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wayne State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine impact of Sleep Disordered Breathing (SDB) treatment&#xD;
      in persons with chronic Spinal Cord Injury (SCI). The central hypothesis is that the&#xD;
      treatment of SDB with Positive Airway Pressure (PAP) will improve cognition, sleep quality,&#xD;
      health related quality of life (HRQOL), pain and Cardiovascular Disease (CVD) surrogate&#xD;
      measures in persons with chronic SCI.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigators will examine the effect of PAP therapy and sleep apnea on thinking (especially&#xD;
      memory, learning and concentration), sleep quality, and risks for future heart&#xD;
      (cardiovascular) problems in persons with chronic spinal cord injury (SCI).&#xD;
&#xD;
      SDB is a condition where there are pauses in breathing or shallow breathing during sleep due&#xD;
      to airway narrowing. This leads to low oxygen levels during sleep and sleep disruption. The&#xD;
      usual treatment for sleep apnea is PAP (Positive Airway Pressure) worn while sleeping. This&#xD;
      involves the use of usually a mask connected to a machine that supplies enough pressure to&#xD;
      keep the airway open during sleep.&#xD;
&#xD;
      SDB will be diagnosed in SCI participants using unattended portable level II polysomnography&#xD;
      (PSG) (a portable at home sleep study for one night).&#xD;
&#xD;
      Sleep quality (SQ), SDB risk, insomnia severity, daytime sleepiness,and mood will be measured&#xD;
      using questionnaires.&#xD;
&#xD;
      Cognitive evaluations will be completed prior to randomization on all participants who also&#xD;
      complete a portable PSG to evaluate general and pre-morbid function, immediate verbal memory,&#xD;
      simple and sustained attention, processing speed, and executive function.&#xD;
&#xD;
      Blood and urine samples will be taken for participants with SDB diagnosis after&#xD;
      randomization.&#xD;
&#xD;
      All randomized subjects will be fitted with a nasal or full-face mask and head gear. PAP will&#xD;
      be delivered by an auto-titrating device. These devices automatically set the level of&#xD;
      delivered pressure to ensure upper airway patency, to treat detected apneas, and hypopneas.&#xD;
      All subjects will be instructed to use the device nightly during sleep, for the ensuing four&#xD;
      months. All outcome measurements will be reassessed after four months of PAP.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2014</start_date>
  <completion_date type="Actual">September 30, 2018</completion_date>
  <primary_completion_date type="Actual">September 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cognitive Functioning as Measured by PASAT</measure>
    <time_frame>16 weeks</time_frame>
    <description>Paced Serial Addition Test (PASAT) measures divided attention and memory. PASAT has a total score ranging from 0 to 60 with the lower scores indicate greater impairment of attention.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Spinal Cord Injury</condition>
  <condition>Sleep Apnea, Obstructive</condition>
  <arm_group>
    <arm_group_label>AutoPAP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PAP treatment will be delivered for four months by an auto-titrating device (IntelliPAP AutoAdjust®). These devices automatically set the level of delivered pressure to ensure upper airway patency, to treat detected apneas and hypopneas.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham PAP</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham PAP treatment will be delivered for four months by an auto-PAP device (IntelliPAP AutoAdjust®) that is set to a fixed low pressure of 3 cmH20 without an ability to titrate according to detected respiratory events.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AutoPAP</intervention_name>
    <description>PAP will be delivered by an auto-titrating device (IntelliPAP AutoAdjust®). These devices automatically set the level of delivered pressure to ensure upper airway patency, to treat detected apneas and hypopneas.&#xD;
AutoPAP treatment 7 nights a week for four months (16 weeks).</description>
    <arm_group_label>AutoPAP</arm_group_label>
    <other_name>IntelliPAP AutoAdjust®</other_name>
    <other_name>CPAP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham PAP</intervention_name>
    <description>Sham PAP treatment will be delivered by an auto-PAP device (IntelliPAP AutoAdjust®) that is set to a fixed low pressure of 3 cmH20 without an ability to titrate according to detected respiratory events. The pressure is too low to eliminate respiratory events and serves as sham or sub-therapeutic PAP.&#xD;
Sham PAP treatment 7 nights a week for four months (16 weeks)./</description>
    <arm_group_label>Sham PAP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Chronic tetraplegia or paraplegia (C4-L1)&#xD;
&#xD;
          -  American Spinal Injury Association (ASIA) Impairment Scale A, B, C or D&#xD;
&#xD;
          -  18 years and older&#xD;
&#xD;
          -  At least one year post injury&#xD;
&#xD;
          -  Hearing and vision suitable for comprehension of instructions, and perception of&#xD;
             cognitive test stimuli&#xD;
&#xD;
          -  No color blindness as measured by a brief screen with color perception Ishihara cards&#xD;
&#xD;
          -  Stable medical condition for 2 weeks prior to enrollment. Patients admitted to&#xD;
             hospital will be eligible for enrolment if the acute illness precipitating admission&#xD;
             is in recovery phase for 2 weeks or longer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of SDB and successful positive airway pressure (PAP) therapy prior to&#xD;
             injury. Those with a diagnosis of SDB post injury who are not receiving therapy for&#xD;
             SDB (PAP, surgical, and/or oral appliance) are eligible for study enrollment&#xD;
&#xD;
          -  Patients who are intubated, have a tracheostomy, and/or are using long term&#xD;
             invasive/non-invasive positive pressure ventilation&#xD;
&#xD;
          -  Participants with predominant central sleep apnea on PSG requiring bi-level PAP&#xD;
             therapy&#xD;
&#xD;
          -  Severe traumatic brain injury (GCS &lt; 8 at first assessment)&#xD;
&#xD;
          -  Unable to understand or read English at a grade 5 level&#xD;
&#xD;
          -  Inability to provide informed consent&#xD;
&#xD;
          -  Evidence of advanced neurological or systemic disease that may affect cognitive&#xD;
             functioning (e.g., Alzheimer's disease, Dementia, Parkinson's disease)&#xD;
&#xD;
          -  Significant aphasia or language impairments&#xD;
&#xD;
          -  Positive airway pressure therapy may be contraindicated in some patients with the&#xD;
             following preexisting conditions:&#xD;
&#xD;
          -  severe bullous lung disease&#xD;
&#xD;
          -  pneumothorax&#xD;
&#xD;
          -  pathologically low blood pressure&#xD;
&#xD;
          -  dehydration&#xD;
&#xD;
          -  cerebrospinal fluid leak, recent cranial surgery, or trauma.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shirin Shafazand, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami Miller School of Medicine; Pulmonary and Critical Care Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Miami VA Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Project to Cure Paralysis, University of Miami Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John D Dingell VA Medical Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>June 25, 2014</study_first_submitted>
  <study_first_submitted_qc>June 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2014</study_first_posted>
  <results_first_submitted>November 25, 2019</results_first_submitted>
  <results_first_submitted_qc>October 29, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 2, 2020</results_first_posted>
  <last_update_submitted>October 29, 2020</last_update_submitted>
  <last_update_submitted_qc>October 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Shirin Shafazand</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
    <mesh_term>Spinal Cord Injuries</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 25, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT02176928/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>AutoPAP</title>
          <description>PAP treatment will be delivered for four months by an auto-titrating device (IntelliPAP AutoAdjust®). These devices automatically set the level of delivered pressure to ensure upper airway patency, to treat detected apneas and hypopneas.&#xD;
AutoPAP: PAP will be delivered by an auto-titrating device (IntelliPAP AutoAdjust®). These devices automatically set the level of delivered pressure to ensure upper airway patency, to treat detected apneas and hypopneas.&#xD;
AutoPAP treatment 7 nights a week for four months (16 weeks).</description>
        </group>
        <group group_id="P2">
          <title>Sham PAP</title>
          <description>Sham PAP treatment will be delivered for four months by an auto-PAP device (IntelliPAP AutoAdjust®) that is set to a fixed low pressure of 3 cmH20 without an ability to titrate according to detected respiratory events.&#xD;
Sham PAP: Sham PAP treatment will be delivered by an auto-PAP device (IntelliPAP AutoAdjust®) that is set to a fixed low pressure of 3 cmH20 without an ability to titrate according to detected respiratory events. The pressure is too low to eliminate respiratory events and serves as sham or sub-therapeutic PAP.&#xD;
Sham PAP treatment 7 nights a week for four months (16 weeks)./</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AutoPAP</title>
          <description>PAP treatment will be delivered for four months by an auto-titrating device (IntelliPAP AutoAdjust®). These devices automatically set the level of delivered pressure to ensure upper airway patency, to treat detected apneas and hypopneas.&#xD;
AutoPAP: PAP will be delivered by an auto-titrating device (IntelliPAP AutoAdjust®). These devices automatically set the level of delivered pressure to ensure upper airway patency, to treat detected apneas and hypopneas.&#xD;
AutoPAP treatment 7 nights a week for four months (16 weeks).</description>
        </group>
        <group group_id="B2">
          <title>Sham PAP</title>
          <description>Sham PAP treatment will be delivered for four months by an auto-PAP device (IntelliPAP AutoAdjust®) that is set to a fixed low pressure of 3 cmH20 without an ability to titrate according to detected respiratory events.&#xD;
Sham PAP: Sham PAP treatment will be delivered by an auto-PAP device (IntelliPAP AutoAdjust®) that is set to a fixed low pressure of 3 cmH20 without an ability to titrate according to detected respiratory events. The pressure is too low to eliminate respiratory events and serves as sham or sub-therapeutic PAP.&#xD;
Sham PAP treatment 7 nights a week for four months (16 weeks)./</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.5" spread="9.6"/>
                    <measurement group_id="B2" value="46.9" spread="14.3"/>
                    <measurement group_id="B3" value="44.2" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cognitive Functioning as Measured by PASAT</title>
        <description>Paced Serial Addition Test (PASAT) measures divided attention and memory. PASAT has a total score ranging from 0 to 60 with the lower scores indicate greater impairment of attention.</description>
        <time_frame>16 weeks</time_frame>
        <population>2 sham participants did not complete PASAT at 16 weeks</population>
        <group_list>
          <group group_id="O1">
            <title>AutoPAP</title>
            <description>PAP treatment will be delivered for four months by an auto-titrating device (IntelliPAP AutoAdjust®). These devices automatically set the level of delivered pressure to ensure upper airway patency, to treat detected apneas and hypopneas.&#xD;
AutoPAP: PAP will be delivered by an auto-titrating device (IntelliPAP AutoAdjust®). These devices automatically set the level of delivered pressure to ensure upper airway patency, to treat detected apneas and hypopneas.&#xD;
AutoPAP treatment 7 nights a week for four months (16 weeks).</description>
          </group>
          <group group_id="O2">
            <title>Sham PAP</title>
            <description>Sham PAP treatment will be delivered for four months by an auto-PAP device (IntelliPAP AutoAdjust®) that is set to a fixed low pressure of 3 cmH20 without an ability to titrate according to detected respiratory events.&#xD;
Sham PAP: Sham PAP treatment will be delivered by an auto-PAP device (IntelliPAP AutoAdjust®) that is set to a fixed low pressure of 3 cmH20 without an ability to titrate according to detected respiratory events. The pressure is too low to eliminate respiratory events and serves as sham or sub-therapeutic PAP.&#xD;
Sham PAP treatment 7 nights a week for four months (16 weeks)./</description>
          </group>
        </group_list>
        <measure>
          <title>Cognitive Functioning as Measured by PASAT</title>
          <description>Paced Serial Addition Test (PASAT) measures divided attention and memory. PASAT has a total score ranging from 0 to 60 with the lower scores indicate greater impairment of attention.</description>
          <population>2 sham participants did not complete PASAT at 16 weeks</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" spread="7.6"/>
                    <measurement group_id="O2" value="15.2" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>AutoPAP</title>
          <description>PAP treatment will be delivered for four months by an auto-titrating device (IntelliPAP AutoAdjust®). These devices automatically set the level of delivered pressure to ensure upper airway patency, to treat detected apneas and hypopneas.&#xD;
AutoPAP: PAP will be delivered by an auto-titrating device (IntelliPAP AutoAdjust®). These devices automatically set the level of delivered pressure to ensure upper airway patency, to treat detected apneas and hypopneas.&#xD;
AutoPAP treatment 7 nights a week for four months (16 weeks).</description>
        </group>
        <group group_id="E2">
          <title>Sham PAP</title>
          <description>Sham PAP treatment will be delivered for four months by an auto-PAP device (IntelliPAP AutoAdjust®) that is set to a fixed low pressure of 3 cmH20 without an ability to titrate according to detected respiratory events.&#xD;
Sham PAP: Sham PAP treatment will be delivered by an auto-PAP device (IntelliPAP AutoAdjust®) that is set to a fixed low pressure of 3 cmH20 without an ability to titrate according to detected respiratory events. The pressure is too low to eliminate respiratory events and serves as sham or sub-therapeutic PAP.&#xD;
Sham PAP treatment 7 nights a week for four months (16 weeks)./</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>only 39% of subjects were using PAP more than 4 hours a night by end of week 1 and this number dropped to less than 30% by end of month 4, this may impact final conclusions. Small sample size.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Shirin Shafazand, MD, MS</name_or_title>
      <organization>University of Miami</organization>
      <phone>305-243-7888</phone>
      <email>sshafazand@med.miami.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

